Gareth W. Langley

Gareth W. Langley

Auto-generated profile, based on publicly available information

Gareth W. Langley

Charles River Laboratories, Saffron Walden, United Kingdom

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2021 in Nature Chemistry
Verified
Journal Article
Closed access
PDF file
JBJurgen Brem
Jurgen Brem
TPTharindi Panduwawala
Tharindi Panduwawala
JHJon Ulf Hansen
Jon Ulf Hansen
JHJoanne Hewitt
Joanne Hewitt
ELEdgars Liepins
Edgars Liepins
CSChristopher J. Schofield
Christopher J. Schofield

1 July 2020 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
LTLucas Tselepis
Lucas Tselepis
GLGareth W. Langley
Gareth W. Langley
AAAli F. Aboklaish
Ali F. Aboklaish
EWEmma Widlake
Emma Widlake
DJDana E. Jackson
Dana E. Jackson
JTJonathan M. Tyrrell
Jonathan M. Tyrrell

1 August 2019 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Open access
GLGareth W. Langley
Gareth W. Langley
RCRicky Cain
Ricky Cain
JTJonathan M. Tyrrell
Jonathan M. Tyrrell
PHPhilip Hinchliffe
Philip Hinchliffe
KCKarina Calvopiña
Karina Calvopiña
JBJurgen Brem
Jurgen Brem
β-Lactams are the most successful antibacterials, yet their use is threatened by resistance, importantly as caused by β-lactamases. β-Lactamases fall into two mechanistic groups: the serine β-lactamases that utilise a covalent acyl-enzyme mechanism and the metallo β-lactamases that utilise a zinc-bound water nucleophile. Achieving simultaneous inhibition of both β-lactamase classes remains a challenge in the field. Vaborbactam is a boronate-based inhibitor that reacts with serine-β-lactamases to form covalent complexes that mimic tetrahedral intermediates in catalysis. Vaborbactam has recently been approved for clinical use in combination with the carbapenem meropenem. Here we show that vaborbactam moderately inhibits metallo-β-lactamases from all 3 subclasses (B1, B2 and B3), with a potency of around 20-100 fold below that by which it inhibits its current clinical targets, the Class A serine β-lactamases. This result contrasts with recent investigations of bicyclic boronate inhibitors, which potently inhibit subclass B1 MBLs but which presently lack activity against B2 and B3 enzymes. These findings indicate that cyclic boronate scaffolds have the potential to inhibit the full range of β-lactamases and justify further work on the development of boronates as broad-spectrum β-lactamase inhibitors.

5 August 2019 in Chemical Communications
Verified
Journal Article
Open access
PDF file
MMMariska de Munnik
Mariska de Munnik
CLChristopher T. Lohans
Christopher T. Lohans
PLPauline Lang
Pauline Lang
GLGareth W. Langley
Gareth W. Langley
TMTika R. Malla
Tika R. Malla
JBJurgen Brem
Jurgen Brem
The L,D-transpeptidases (Ldts) are promising antibiotic targets for treating tuberculosis. We report screening of cysteine-reactive inhibitors against LdtMt2 from Mycobacterium tuberculosis. Structural studies on LdtMt2 with potent inhibitor ebselen reveal opening of the benzisoselenazolone ring by a nucleophilic cysteine, forming a complex involving extensive hydrophobic interactions with a substrate-binding loop.

19 July 2019 in ChemBioChem
Verified
Journal Article
Open access
PDF file
MMMariska de Munnik
Mariska de Munnik
CLChristopher T. Lohans
Christopher T. Lohans
GLGareth W. Langley
Gareth W. Langley
CBCorentin BON
Corentin BON
JBJurgen Brem
Jurgen Brem
CSChristopher J. Schofield
Christopher J. Schofield
Mycobacterium tuberculosis l,d‐transpeptidases (Ldts), which are involved in cell‐wall biosynthesis, have emerged as promising targets for the treatment of tuberculosis. However, an efficient method for testing inhibition of these enzymes is not currently available. We present a fluorescence‐based assay for LdtMt2, which is suitable for high‐throughput screening. Two fluorogenic probes were identified that release a fluorophore upon reaction with LdtMt2, thus making it possible to assess the availability of the catalytic site in the presence of inhibitors. The assay was applied to a panel of β‐lactam antibiotics and related inhibitors; the results validate observations that the (carba)penem subclass of β‐lactams are more potent Ldt inhibitors than other β‐lactam classes, though unexpected variations in potency were observed. The method will enable systematic structure–activity relationship studies on Ldts, thereby facilitating the identification of new antibiotics active against M. tuberculosis.

21 November 2019 in ChemMedChem
Verified
Journal Article
Open access
PDF file
JHJames P. Holt‐Martyn
James P. Holt‐Martyn
RCRasheduzzaman Chowdhury
Rasheduzzaman Chowdhury
ATAnthony Tumber
Anthony Tumber
TYTzu‐Lan Yeh
Tzu‐Lan Yeh
MAMartine I. Abboud
Martine I. Abboud
CSChristopher J. Schofield
Christopher J. Schofield
The 2‐oxoglutarate‐dependent hypoxia inducible factor prolyl hydroxylases (PHDs) are targets for treatment of a variety of diseases including anaemia. One PHD inhibitor is approved for use for the treatment of renal anaemia and others are in late stage clinical trials. The number of reported templates for PHD inhibition is limited. We report structure–activity relationship and crystallographic studies on a promising class of 4‐hydroxypyrimidine‐containing PHD inhibitors.